Michael Grobstein - Bristol Myers Independent Director

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 40px;;'>BMY</div>
BMY -- USA Stock  

Fiscal Quarter End: March 31, 2020  

Mr. Michael Grobstein is Independent Director of BristolMyers Squibb Company. Mr. Grobstein is a Retired as Vice Chairman of Ernst Young LLP, an independent registered public accounting firm. He worked with Ernst Young from 1964 until 1998, and was admitted as a partner in 1975
Age: 75  Director Since 2007      
212 546-4020  www.bms.com
Grobstein served as a Vice Chairman?International Operations from 1993 until 1998, as Vice Chairman?Planning, Marketing and Industry Services from 1987 until 1993, and as Vice Chairman?Accounting and Auditing Services from 1984 until 1987. He serves on the Board of Trustees and Executive Committee and is the Treasurer of the Central Park Conservancy. He also serves on the Board of Directors of the Peer Health Exchange, Inc. During the last five years, Mr. Grobstein was a Director of Mead Johnson Nutrition Company and Given Imaging Ltd.

Management Efficiency

The company has Return on Asset of 0.12 % which means that on every $100 spent on asset it made $0.12 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.28 % implying that it generated $0.28 on every 100 dollars invested.
The company has 25.8 B in debt with debt to equity (D/E) ratio of 159.7 . This implies that the company may be unable to create cash to meet all of its financial commitments. Bristol Myers Squibb has Current Ratio of 3.8 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Shriti VaderaAstrazeneca PLC
Tony MokAstrazeneca PLC
Genevieve BergerAstrazeneca PLC
Catherine KlemaAllergan Plc
Nazneen RahmanAstrazeneca PLC
Shantanu NarayenPfizer
Elizabeth DohertyNovartis AG
Inge ThulinMerck Company
Karen HornEli Lilly And Company
Ralph AlvarezEli Lilly And Company
Thomas FreymanAllergan Plc
Franklyn PrendergastEli Lilly And Company
Marc DunoyerAstrazeneca PLC
Joseph BoccuziAllergan Plc
Anne MulcahyJohnson Johnson
Vivienne CoxGlaxoSmithKline PLC
Baroness VaderaAstrazeneca PLC
Mary ColemanJohnson Johnson
Frans HoutenNovartis AG
James BloemAllergan Plc
Jackson TaiEli Lilly And Company

Company Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange.Bristol Myers Squibb Company (BMY) is traded on BATS Exchange in USA. It is located in 430 E. 29th Street 14th Floor, New York, NY 10016, United States and employs 23,300 people. Bristol Myers is listed under Pharmaceutical Products category by Fama And French industry classification.

Bristol Myers Squibb Leadership Team

Ann Powell, Chief Human Resource Officer, Senior Vice PresidentView
Togo West, Independent DirectorView
Karen Vousden, Independent DirectorView
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics OfficerView
Michael Bonney, DirectorView
Alan Lacy, Independent DirectorView
Robert Bertolini, Independent DirectorView
Jose Baselga, Independent DirectorView
Charles Bancroft, Chief Financial Officer, Executive Vice President - Global Business OperationsView
Gerald Storch, Independent DirectorView
Louis Schmukler, Senior Vice President, President - Global Product Development and SupplyView
Michael Grobstein, Independent DirectorView
Christopher Boerner, Executive Vice President and Chief Commercial OfficerView
Phyllis Yale, DirectorView
John Elicker, Senior Vice President - Corporate Affairs and Investor RelationsView
Anne Nielsen, Senior Vice President Chief Compliance and Ethics OfficerView
Karen Santiago, Senior Vice President, Corporate ControllerView
Giovanni Caforio, Chairman of the Board, Chief Executive OfficerView
Vicki Sato, Lead Independent DirectorView
Emmanuel Blin, Senior Vice President Chief Strategy OfficerView
Joseph Caldarella, Senior Vice President Corporate ControllerView
Julia Haller, DirectorView
Laurie Glimcher, Independent DirectorView
Murdo Gordon, Executive Vice President Chief Commercial OfficerView
Lamberto Andreotti, Executive Chairman, Officer, Ex-Officio Member of Audit Committee, Ex-Officio Member of Committee on Directors and Corporate Governance and Ex-Officio Member of Compensation and Management Devel. CommitteeView
Thomas Lynch, Chief Scientific Officer, Executive Vice PresidentView
Lewis Campbell, Independent DirectorView
Dinesh Paliwal, Independent DirectorView
Theodore Samuels, Independent DirectorView
Samuel Moed, Senior Vice President - Strategic Planning and AnalysisView
Matthew Emmens, Independent DirectorView
Ann Judge, Chief Human Resource Officer, Senior Vice PresidentView
Sandra Leung, Executive Vice President, General CounselView
Paul Autenried, Chief Information Officer, Senior Vice PresidentView
Francis Cuss, Executive Vice President Chief Scientific OfficerView
Paul Biondi, Senior Vice President, Head of Strategy & Business DevelopmentView
Kathryn Metcalfe, Executive Vice President - Corporate AffairsView
Peter Arduini, Independent DirectorView

Stock Performance Indicators

Current Sentiment - BMY

Bristol Myers Squibb Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Bristol Myers Squibb Company. What is your opinion about investing in Bristol Myers Squibb Company? Are you bullish or bearish?
98% Bullish
2% Bearish

Bristol Myers Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol Myers and Allergan Plc. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Please also try Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..